NYSE$SYK

Stryker Corp · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Stryker's Q2 2020 results were negatively impacted by COVID-19, with net sales decreasing by 24.3% and a reported EPS loss of $0.22.

Stryker's Q2 2020 results were significantly impacted by the COVID-19 pandemic, leading to a 24.3% decrease in reported net sales to $2.8 billion. The company reported a net loss of $83 million, or $0.22 per diluted share, but adjusted EPS was $0.64. Due to the uncertain scope and duration of the pandemic, Stryker is not providing third quarter or full-year organic sales growth or earnings guidance for 2020.

  • Reported net sales decreased 24.3% to $2.8 billion.
  • Organic net sales decreased 24.0%.
  • Reported EPS decreased 117.5% to ($0.22).
  • Adjusted EPS decreased 67.7% to $0.64.

Headline financials

Total Revenue

$2.76B

Previous: $3.65B-24.3%
EPS (adj)

$0.64

Previous: $1.98-67.7%
Organic Net Sales Growth

-24.0%

No prior period
Capital Expenditures

-$253M

Previous: -$287M+11.8%
Free Cash Flow

-$336M

Previous: $193M-274.1%
Net Income

-$83M

Previous: $480M-117.3%
Operating Income

-$20M

Previous: $613M-103.3%
Gross Profit

$1.55B

Previous: $2.38B-35.0%
Cash & Equivalents

$6.54B

Previous: $1.75B+272.8%
Total Assets

$31.5B

Previous: $26.4B+19.5%
Stock-Based Comp

$30M

Previous: $28M+7.1%

Revenue & EPS history

Stryker · Revenue · Quarterly

$2.76B

Q2 2020-24.3%vs Q2 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Stryker · $894M total across 1 segment · Q2 2020

  • Orthopaedics
    $894M-29.8%

Forward guidance

Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, Stryker is unable to estimate the overall impacts on our operations and financial results, which could be material. Accordingly, Stryker will not be providing third quarter or full-year organic sales growth or earnings guidance for 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+0.7%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+1.7%

Avg return

30 days after

58%

42 / 73 earnings

Positive

+11.8%

Q4 2022

Best reaction

-6.3%

Q1 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.4%-7.2%-3.0%
Q4 2025+2.6%+1.8%+9.4%
Q3 2025-3.0%-3.1%+0.6%
Q2 2025+0.0%-0.4%+3.6%
Q1 2025+1.0%+2.7%+2.3%
Q4 2024-2.2%-2.2%-2.8%
Q3 2024+2.1%+3.1%+9.0%
Q2 2024-1.7%-0.5%+7.4%
Q1 2024-3.2%-3.1%+0.5%
Q4 2023+6.7%+8.8%+11.0%
Q3 2023+1.5%+1.1%+9.5%
Q2 2023+3.3%+2.8%+3.6%
Q1 2023-1.9%-5.0%-8.0%
Q4 2022+11.8%+13.5%+5.0%
Q3 2022-4.0%-8.0%+2.0%
Q2 2022+5.1%+6.6%+7.5%
Q1 2022-3.2%-4.5%-5.1%
Q4 2021+0.1%+0.1%+7.1%
Q3 2021-0.9%+1.5%-9.3%
Q2 2021+2.0%+2.8%+2.9%
Q1 2021-2.1%-1.0%-4.1%
Q4 2020-3.4%-4.8%+2.0%
Q3 2020-1.4%+1.6%+13.6%
Q2 2020-4.0%-6.0%-1.6%
Q1 2020-6.3%-2.5%+1.6%
Q4 2019-1.8%-1.8%-9.2%
Q3 2019+1.6%-0.4%-4.1%
Q2 2019+0.4%+0.0%+0.2%
Q1 2019+1.6%+3.4%+1.3%
Q4 2018+10.7%+9.5%+16.4%
Q3 2018-1.7%-0.7%+1.0%
Q2 2018-2.7%-3.2%-3.0%
Q1 2018+3.2%+2.2%+5.1%
Q4 2017-2.6%-3.9%-5.6%
Q3 2017+6.4%+3.1%+3.0%
Q2 2017+1.4%+1.5%-4.0%
Q1 2017+1.3%+1.4%+4.8%
Q4 2016-0.2%+3.3%+3.6%
Q3 2016+4.0%+4.5%+2.7%
Q2 2016-4.4%-4.8%-7.0%
Q1 2016-0.4%
Q4 2015+4.4%
Q3 2015-5.4%
Q2 2015+2.5%
Q1 2015+3.3%
Q4 2014+0.2%
Q3 2014+1.0%
Q2 2014-0.2%
Q1 2014-1.1%
Q4 2013-1.0%
Q3 2013+2.7%
Q2 2013+2.2%
Q1 2013+1.1%
Q4 2012+2.8%
Q3 2012+0.3%
Q2 2012-2.9%
Q1 2012+2.2%
Q4 2011-0.0%
Q3 2011-2.9%
Q2 2011-0.3%
Q1 2011+0.2%
Q4 2010+1.9%
Q3 2010+2.3%
Q2 2010-0.7%
Q1 2009-1.1%
Q1 2010+0.2%
Q4 2009+1.9%
Q4 2007+1.9%
Q3 2008+2.9%
Q3 2009+2.9%
Q2 2009+5.1%
Q2 2008+5.1%
Q4 2008+5.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro